"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Patients should be informed that the most common adverse reactions for the indication of postoperative nausea and vomiting are pain, headache, fever, abdominal pain and hepatic enzyme increased (see Table 2).
Electrocardiogram changes (QT prolongation) have been reported with the use of KYTRIL. Patients should be cautioned about the use of this drug if they have heart problems or take medications for heart problems.
Patients should be informed that KYTRIL Injection (1 mg/mL) contains benzyl alcohol and may cause serious side effects in newborns. KYTRIL Injection 0.1 mg/mL contains no benzyl alcohol.
Last reviewed on RxList: 6/22/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Kytril Injection Information
Kytril Injection - User Reviews
Kytril Injection User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.